Will risk compensation accompany pre-exposure prophylaxis for HIV?
Will risk compensation accompany pre-exposure prophylaxis for HIV?
复制标题
DOI：
10.1001/virtualmentor.2014.16.11.stas1-1411
复制
发表时间：
2014-11-01
期刊：
影响因子：
--
通讯作者：
Haubrich, Richard H
中科院分区：
文献类型：
--
作者：
Blumenthal, Jill;Haubrich, Richard H
艾滋病毒流行已三十年，仍然需要可在新感染高发人群中实施的可行且有效的预防策略。理想的预防方案应满足人群中每个亚群体的需求，并且是可接受的、可及的和有效的。通过结合几种行之有效的预防策略，可以最好地实现艾滋病毒的控制，包括使用安全套、医疗男性包皮环切术、艾滋病毒抗体检测以及针对艾滋病毒感染者的治疗即预防 (TasP) 的抗逆转录病毒治疗 (ART) 和针对未感染艾滋病毒的人的暴露前预防 (PrEP) [(1)]。结合抗逆转录病毒治疗的生物医学干预措施最有可能对该流行病产生最大的影响；它们已在多项随机安慰剂对照试验 [(2-6)] 和开放标签扩展中被证明是有效的，其中研究人员和参与者知道正在使用活性药物 [(7)]。
Thirty years into the HIV epidemic, feasible and effective prevention strategies that can be implemented in populations with high incidence of new infection are still needed. An ideal prevention package should meet the needs of each subgroup in a population and be acceptable, accessible, and effective. Control of HIV will be best accomplished by combining several proven prevention strategies, including condom use, medical male circumcision, HIV antibody testing, and antiretroviral therapy (ART) for treatment as prevention (TasP) for those infected with HIV and pre-exposure prophylaxis (PrEP) for those not infected with HIV [(1)]. Biomedical interventions incorporating ART are most likely to have the greatest impact on the epidemic; they have been shown to be effective in several randomized placebo control trials [(2–6)] and open-label extensions, in which researchers and participants knew the active drug was being used [(7)].